

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2026 P 2417-1
Program	Prior Authorization/Medical Necessity
Medication	Kygevvi® (doxecitine and doxribtimine)
P&T Approval Date	5/2026
Effective Date	7/1/2026

1. Background:

Kygevvi (doxecitine and doxribtimine) is a combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.

2. Coverage Criteria^a:

A. Initial Authorization

1. **Kygevvi** will be approved based upon **all** of the following criteria:

a. Diagnosis of thymidine kinase 2 deficiency (TK2d)

-AND-

b. Diagnosis confirmed by the presence of a mutation in the *TK2* gene

-AND-

c. Age of symptom onset \leq 12 years

-AND-

d. Prescribed by, or in consultation with, a geneticist or neuromuscular specialist with expertise in the treatment of TK2d

Authorization will be issued for 12 months.

B. Reauthorization

1. **Kygevvi** will be approved based on **both** of the following criteria:

a. Physician attestation that patient would benefit from continued administration.

-AND-

b. Prescribed by, or in consultation with, a geneticist or neuromuscular specialist with expertise in the treatment of TK2d

Authorization will be issued for 12 months.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

4. Reference:

1. Kygeevi [package insert]. Smyrna, GA: UCB, Inc.; November 2025.

Program	Prior Authorization/Medical Necessity - Kygeevi (doxecitine and doxribtimine)
Change Control	
5/2026	New program.